PEGBIO CO-B (02565) announced its annual results for the period ending December 31, 2025. The Group recorded other net income of RMB189,000 and research and development expenses of RMB50.387 million. The basic loss per share was RMB0.55. As of the date of this announcement, significant progress has been made in advancing technological innovation, product pipelines, and business operations in both the United States and China. PEGBIO has successfully established a pipeline matrix covering seven investigational drugs targeting chronic disease areas. The company's core strategy focuses on the treatment of metabolic diseases and their complications. Through continuous innovation, internal evaluations indicate that multiple drug candidates possess the dual potential of being both "first-in-class" (FIC) and "best-in-class" (BIC), laying a solid foundation for future market competitiveness. Following the successful market approval of its core product, Paidacone® (PB-119), in November 2025, the Group will fully advance its commercialization efforts in the Chinese market. Moving forward, the Group will continue its work related to post-market access, the refinement of its commercial operations system, and improving patient accessibility. These efforts are aimed at supporting market penetration and expanding clinical usage scenarios after product launch, thereby gradually realizing the products' value.